pre-IPO PHARMA

COMPANY OVERVIEW

XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. The Company’s lead product candidate, XC001, is in clinical development to investigate use for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. Co‑founded by Ronald Crystal, MD, and Todd Rosengart, MD, XyloCor has a licensing agreement with Weill Cornell Medicine for the worldwide rights to develop, manufacture and commercialize XC001.


LOCATION

  • Malvern, PA, USA

  • THERAPEUTIC AREAS

  • Cardiovascular Disease

  • WEBSITE

    http://xylocor.com


    CAREER WEBSITE

    http://xylocor.com/careers.html


    SOCIAL MEDIA


    INVESTORS

    lsp sofinnova-investments


    PRESS RELEASES


    Jun 28, 2022

    XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease


    May 18, 2022

    XyloCor Therapeutics Announces Presentation of Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina at AATS and ASGCT


    Jan 18, 2022

    XyloCor Therapeutics Expands Leadership Team with Accomplished Pharmaceutical Executives to Accelerate Clinical Development Programs and Drive Corporate Growth


    Jul 27, 2021

    XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina


    Mar 22, 2021

    XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease


    For More Press Releases


    Google Analytics Alternative